布地奈德联合阿奇霉素治疗支气管哮喘的效果研究

Study on effect of budesonide combined with azithromycin in the treatment of bronchial asthma

目的探究支气管哮喘患者联合使用阿奇霉素与布地奈德的治疗效果。方法110例支气管哮喘患者,随机分为研究组与对照组,各55例。对照组使用阿奇霉素治疗,研究组使用布地奈德联合阿奇霉素治疗。对比两组患者症状改善时间、治疗效果、肺功能及炎症指标[第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、C反应蛋白]、不良事件发生情况及生活质量。结果研究组患者气喘、呼吸困难、肺部杂音以及咳嗽改善时间分别为(3.37±1.26)、(2.04±0.21)、(5.02±0.44)、(4.03±0.57)d,均短于对照组的(6.37±2.12)、(3.56±1.22)、(8.17±1.26)、(5.21±0.43)d,比较可知有统计学价值(P<0.05)。研究组治疗总有效率96.36%显著高于对照组的78.18%,比较可知有统计学价值(P<0.05)。研究组不良事件发生率较对照组更低,比较可知有统计学价值(P<0.05)。研究组患者FEV1(2.75±0.68)L与FVC(3.65±0.84)L显著高于对照组的(2.22±0.37)、(2.71±0.76)L,C反应蛋白(2.66±0.56)mg/L低于对照组的(5.07±0.88)mg/L,比较可知有统计学价值(P<0.05)。研究组患者躯体疼痛、生命活力、生理功能以及情感功能评分分别为(83.57±7.21)、(84.66±9.18)、(85.36±9.07)、(83.21±9.54)分,均高于对照组的(76.44±8.34)、(80.30±8.09)、(80.49±8.36)、(75.64±8.56)分,比较可知有统计学价值(P<0.05)。结论联合使用阿奇霉素与布地奈德可有效改善支气管哮喘患者的肺功能及炎症指标,提升治疗效果,预防不良事件,从而改善患者生活质量。

Objective To explore the effect of budesonide combined with azithromycin in the treatment of bronchial asthma.Methods 110 patients with bronchial asthma were randomly divided into a study group and a control group,with 55 cases in each group.The control group was treated with azithromycin,and the study group was treated with budesonide combined with azithromycin.Comparison was made on symptom improvement time,therapeutic effect,pulmonary function and inflammatory indicators[forced expiratory volume in one second(FEV1),forced vital capacity(FVC),C-reactive protein],adverse events and quality of life between the two groups.Results The improvement time of asthma,dyspnea,pulmonary murmur and cough in the study group were(3.37±1.26),(2.04±0.21),(5.02±0.44)and(4.03±0.57)d,which were shorter than(6.37±2.12),(3.56±1.22),(8.17±1.26)and(5.21±0.43)d in the control group,and the comparison showed that there was statistical value(P<0.05).The total effective rate of 96.36%in the study group was significantly higher than 78.18%in the control group,and the comparison showed that there was statistical value(P<0.05).The incidence of adverse events in the study group was lower than that in the control group,and the comparison showed that there was statistical value(P<0.05).The study group had FEV1 of(2.75±0.68)L and FVC of(3.65±0.84)L,which were significantly higher than(2.22±0.37)and(2.71±0.76)L in the control group;the study group had lower C-reactive protein of(2.66±0.56)mg/L than(5.07±0.88)mg/L in the control group;the comparison showed that there was statistical value(P<0.05).In the study group,the scores of physical pain,vital vitality,physiological function and emotional function were(83.57±7.21),(84.66±9.18),(85.36±9.07)and(83.21±9.54)points,which were higher than(76.44±8.34),(80.30±8.09),(80.49±8.36)and(75.64±8.56)points in the control group.The comparison showed that there was statistical value(P<0.05).Conclusion The combination of azithromycin and budesonide can effectively improve the pulmonary function and inflammatory indicators of patients with bronchial asthma,improve the therapeutic effect,prevent adverse events,thus improving the quality of life of patients.